M
Markus Maeurer
Researcher at University of Mainz
Publications - 363
Citations - 15888
Markus Maeurer is an academic researcher from University of Mainz. The author has contributed to research in topics: Tuberculosis & Antigen. The author has an hindex of 61, co-authored 336 publications receiving 13172 citations. Previous affiliations of Markus Maeurer include New York Medical College & Champalimaud Foundation.
Papers
More filters
Journal ArticleDOI
Antigen-processing machinery breakdown and tumor growth.
TL;DR: The pathophysiology of the MHC class I and II APM is described, their role in the escape of tumor cells from in vitro recognition by T cells is discussed and their role with malignant transformation of human cells is reviewed.
Journal ArticleDOI
Single-cell landscape of immunological responses in patients with COVID-19.
Ji Yuan Zhang,Xiang Ming Wang,Xudong Xing,Zhe Xu,Chao Zhang,Jin-Wen Song,Xing Fan,Peng Xia,Jun Liang Fu,Si Yu Wang,Ruo Nan Xu,Xiao Peng Dai,Lei Shi,Lei Huang,Tian Jun Jiang,Ming Shi,Yuxia Zhang,Alimuddin Zumla,Alimuddin Zumla,Markus Maeurer,Fan Bai,Fu-Sheng Wang +21 more
TL;DR: The single-cell transcriptional landscape of moderate, severe and convalescent cases of patients with COVID-19 describes the dynamic nature of immune responses during disease progression, and shows a deranged interferon response, profound immune exhaustion with skewed T cell receptor repertoire and broad T cell expansion.
Journal ArticleDOI
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test
Stephen D. Lawn,Peter Mwaba,Peter Mwaba,Matthew Bates,Amy S. Piatek,Heather Alexander,Ben J. Marais,Luis E. Cuevas,Timothy D. McHugh,Lynn S. Zijenah,Nathan Kapata,Nathan Kapata,Ibrahim Abubakar,Ibrahim Abubakar,Ruth McNerney,Michael Hoelscher,Ziad A. Memish,Giovanni Battista Migliori,Peter S. Kim,Markus Maeurer,Marco Schito,Alimuddin Zumla +21 more
TL;DR: The development of the Xpert MTB/RIF assay is undoubtedly a landmark event, clinical and programmatic effects and cost-effectiveness remain to be defined, and a rapid, accurate point-of-care diagnostic test that is affordable and can be readily implemented is urgently needed.
Journal ArticleDOI
Reducing mortality from 2019-nCoV: host-directed therapies should be an option.
TL;DR: The timing of interferon treatment in patients with sepsis, resulting in increased survival, is studied and expansion of anti-2019nCoV-specific T cells, as cellular drugs, could aid to prepare T-cell products for the adjunct treatment of patients with severe 2019-n coV infection.
Journal ArticleDOI
New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
Alimuddin Zumla,Alimuddin Zumla,Stephen H. Gillespie,Michael Hoelscher,Patrick P J Philips,Stewart T. Cole,Ibrahim Abubakar,Timothy D. McHugh,Marco Schito,Markus Maeurer,Andrew J. Nunn +10 more
TL;DR: The need to engage the community in design, implementation, and uptake of research is emphasised, to increase international cooperation between drug developers and health-care providers adopting new regimens.